Items Tagged ‘REVEL trial’

June 5th, 2014

Cyramza With Taxotere Offers Modest Increase in Overall Survival in NSCLC

By

A phase III randomized trial has shown that Cyramza™ (ramucirumab) combined with Taxotere® (docetaxel) extended overall survival 1.4 months in patients with non-small cell lung cancer (NSCLC) when compared to standard second-line therapy (Taxotere alone). The combination therapy also increased progression free survival by 1.5 months. The results were reported at the 2014 American Society […]

View full entry

Tags: cyramza, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, REVEL trial, Stages IIIB-IV Lung Cancer - Non-Small Cell